Found 4339 clinical trials
A Multicentre Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.
- 0 views
- 24 Nov, 2025
- 1 location
Open Label Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC
This is an open label, dose escalation study to evaluate the safety and efficacy of intralesional injection of STP705 in adult patients with Cutaneous Squamous Cell Carcinoma in situ (isSCC, Bowen's disease). The purpose of this trial is to evaluate the safety, tolerability and efficacy of various doses of STP705 …
- 0 views
- 19 Feb, 2024
- 1 location
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.
- 0 views
- 19 Feb, 2024
- 1 location
Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions
Severely calcified coronary stenoses are difficult to treat with percutaneous coronary intervention (PCI) using current techniques and there is little specific evidence on how to best treat these cases. It is hypothesized that balloon lithoplasty is superior to conventional balloons for lesion preparation of severely calcified coronary lesions before stent …
- 0 views
- 19 Feb, 2024
- 6 locations
Connexin Genotypes in Cystic Fibrosis
Background: There is wide variety in lung disease phenotype for the delta F508 (homozygous) genotype. A leukocyte driven inflammation is most important for the pathogenesis of pulmonary disease in CF. Blood cytokines correlate negatively with pulmonary function in delta F508 homozygous patients. Gap junction proteins might be of importance for …
- 0 views
- 19 Feb, 2024
- 3 locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.
- 0 views
- 19 Feb, 2024
- 17 locations
Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma
This study is a open-lable, , single center, phase II clinical study. Target population is patients with locally resectable osteosarcoma. Study objective is to compare the efficacy and safety of camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 …
- 0 views
- 19 Feb, 2024
- 1 location
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.
- 0 views
- 19 Feb, 2024
- 5 locations
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
The purpose of this study is to determine if it is possible to give CPI-613 with the drug Bendamustine for 2 days every 28 days without causing severe side effects. In addition, this study will also test the safety of CPI-613 when given in combination with Bendamustine.
- 0 views
- 19 Feb, 2024
- 1 location
Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia (FORTUNE)
Schizophrenia is a condition that causes symptoms like delusions, hallucinations, reduced motivation and muddled thinking. It is a common, severe and disabling psychiatric illness affecting about 1/100 (1%) of people. It is ranked the third most disabling illness worldwide. Six in seven patients do not recover from the illness in …
- 0 views
- 06 May, 2025
- 1 location